Expression of antimicrobial peptides and proteins in etanercept-treated psoriasis patients

Gambichler, Thilo; Kobus, Stephan; Kobus, A.; Tigges, Christian; Scola, Nina; Altmeyer, Peter; Kreuter, Alexander; Bechara, F. G.; Skrygan, Marina

doi:10.1016/j.regpep.2011.02.001

Cited by 27 publications

(17 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar results were obtained by other authors, who have shown a decreased expression level of S100A7 mRNA [25,26]. In etanercept-treated specimens, the lack of a significant normalization of psoriasin levels is not consistent with a previous study, where, under similar conditions, such decrease achieved a significant value [27]. This discrepancy may be due to different immunohistochemical semiquantitative analytic approaches.…”

Section: Discussionsupporting

confidence: 78%

Effects of adalimumab, etanercept and ustekinumab on the expression of psoriasin (S100A7) in psoriatic skin

D’Amico

Trovato

Skarmoutsou

et al. 2015

Journal of Dermatological Science

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 78%

Effects of adalimumab, etanercept and ustekinumab on the expression of psoriasin (S100A7) in psoriatic skin

D’Amico

Trovato

Skarmoutsou

et al. 2015

Journal of Dermatological Science

View full text Add to dashboard Cite

“…As an important factor in the development of psoriasis, hBD-2 has been shown to be regulated by IL-22, IL-17A, TNF-α, and interferon-γ (IFN-γ) [9] . Additionally, hBD-2 is chemotactic for neutrophils, monocytes/macrophages, immature dendritic cells, and memory T cells through the chemokine receptor CCR2 or CCR6 [6] .…”

Section: Discussionmentioning

confidence: 99%

Serum Human Beta-Defensin-2 Is a Possible Biomarker for Monitoring Response to JAK Inhibitor in Psoriasis Patients

et al. 2017

View full text Add to dashboard Cite

Aims: To analyse the correlation between serum human beta-defensin-2 (hBD-2) levels and response to JAK inhibitor in psoriasis. Methods: We evaluated the psoriasis area and severity index (PASI) and serum hBD-2 levels of 18 psoriasis patients randomized to receive placebo or tofacitinib 5 or 10 mg b.i.d. at baseline, week 8, and week 16. Serum hBD-2 levels were measured by enzyme-linked immunosorbent assay (ELISA). Results: The PASI achieved a dramatic reduction after tofacitinib 5 or 10 mg b.i.d. treatment for 16 weeks (p < 0.05). Serum hBD-2 levels significantly decreased in patients treated with tofacitinib 10 mg b.i.d. compared with baseline and the placebo-treated patients (p < 0.05). A significant correlation was found between hBD-2 levels and PASI (r = 0.52, p < 0.01). A serum hBD-2 level of 1,255.45 pg/mL was a cut-off between mild and moderate-to-severe psoriasis in ROC analysis. Conclusions: Serum hBD-2 level might be a possible biomarker for monitoring psoriasis treatment response and differentiating mild from moderate-to-severe psoriasis.

show abstract

“…Several studies have focused on the associations between cathelicidin ⁄ LL-37 and other therapies of psoriasis. 33,79,80 For example, Vahavihu et al 80 have reported that narrowband UV-B treatment induces cathelicidin expression by correcting vitamin D insufficiency in psoriasis. In addition, Gambichler et al 79 have shown LL-37 expression is downregulated by etanercept, a biologic which blocks the pro-inflammatory cytokine TNF-a, in psoriasis, suggesting that this mechanism might be associated with the clinical improvement.…”

Section: Ll-37 and Vitamin Dmentioning

confidence: 99%

Antimicrobial peptides in the pathogenesis of psoriasis

Morizane

Gallo

2012

The Journal of Dermatology

190

188

View full text Add to dashboard Cite

One characteristic abnormality of lesional skin in psoriasis is the excessive production of antimicrobial peptides and proteins (AMPs). AMPs typically are small (12-50 amino acids), have positive charge and amphipathic structure, and are found in all living organisms including mammals, insects, plants and invertebrates. These peptides are best known for their integral role in killing pathogenic microorganisms; however, in vertebrates, they are also capable of modifying host inflammatory responses by a variety of mechanisms. In psoriatic lesions, many AMPs are highly expressed, and especially the associations between psoriasis and cathelicidin, b-defensins or S100 proteins have been well studied. Among them, a cathelicidin peptide, LL-37, has been highlighted as a modulator of psoriasis development in recent years. AMPs had been thought to worsen psoriatic lesions but recent evidence has also suggested the possibility that the induction of AMPs expression might improve aspects of the disease. Further investigations are needed to uncover a previously underappreciated role for AMPs in modulating the immune response in psoriasis, and to improve disease without the risks of systemic immunosuppressive approaches.

show abstract

Expression of antimicrobial peptides and proteins in etanercept-treated psoriasis patients

Cited by 27 publications

References 22 publications

Effects of adalimumab, etanercept and ustekinumab on the expression of psoriasin (S100A7) in psoriatic skin

Effects of adalimumab, etanercept and ustekinumab on the expression of psoriasin (S100A7) in psoriatic skin

Serum Human Beta-Defensin-2 Is a Possible Biomarker for Monitoring Response to JAK Inhibitor in Psoriasis Patients

Antimicrobial peptides in the pathogenesis of psoriasis

Contact Info

Product

Resources

About